Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $19.57 billion. The enterprise value is $34.81 billion.
Important Dates
The next estimated earnings date is Wednesday, July 30, 2025, before market open.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 1.23% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.15B |
| Shares Change (YoY) | +1.23% |
| Shares Change (QoQ) | +2.29% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 75.10% |
| Float | 1.14B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 6.63 |
| PS Ratio | 1.17 |
| Forward PS | 1.47 |
| PB Ratio | 3.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.58 |
| P/OCF Ratio | 15.46 |
| PEG Ratio | 0.82 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.82, with an EV/FCF ratio of 45.50.
| EV / Earnings | n/a |
| EV / Sales | 2.09 |
| EV / EBITDA | 7.82 |
| EV / EBIT | 10.18 |
| EV / FCF | 45.50 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 2.70.
| Current Ratio | 1.03 |
| Quick Ratio | 0.46 |
| Debt / Equity | 2.70 |
| Debt / EBITDA | 3.69 |
| Debt / FCF | 22.14 |
| Interest Coverage | 3.46 |
Financial Efficiency
Return on equity (ROE) is -19.11% and return on invested capital (ROIC) is 8.44%.
| Return on Equity (ROE) | -19.11% |
| Return on Assets (ROA) | 5.27% |
| Return on Invested Capital (ROIC) | 8.44% |
| Return on Capital Employed (ROCE) | 12.55% |
| Revenue Per Employee | $451,154 |
| Profits Per Employee | -$34,917 |
| Employee Count | 36,830 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.35 |
Taxes
In the past 12 months, Teva Pharmaceutical has paid $802.00 million in taxes.
| Income Tax | 802.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.35% in the last 52 weeks. The beta is 0.61, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -0.35% |
| 50-Day Moving Average | 16.18 |
| 200-Day Moving Average | 17.48 |
| Relative Strength Index (RSI) | 49.81 |
| Average Volume (20 Days) | 11,508,806 |
Short Selling Information
| Short Interest | 35.67M |
| Short Previous Month | 28.43M |
| Short % of Shares Out | 3.13% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.61 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $16.62 billion and -$1.29 billion in losses. Loss per share was -$1.14.
| Revenue | 16.62B |
| Gross Profit | 8.17B |
| Operating Income | 3.42B |
| Pretax Income | 131.00M |
| Net Income | -1.29B |
| EBITDA | 4.45B |
| EBIT | 3.42B |
| Loss Per Share | -$1.14 |
Full Income StatementBalance Sheet
The company has $1.70 billion in cash and $16.94 billion in debt, giving a net cash position of -$15.24 billion or -$13.29 per share.
| Cash & Cash Equivalents | 1.70B |
| Total Debt | 16.94B |
| Net Cash | -15.24B |
| Net Cash Per Share | -$13.29 |
| Equity (Book Value) | 6.27B |
| Book Value Per Share | 5.46 |
| Working Capital | 371.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.27 billion and capital expenditures -$501.00 million, giving a free cash flow of $765.00 million.
| Operating Cash Flow | 1.27B |
| Capital Expenditures | -501.00M |
| Free Cash Flow | 765.00M |
| FCF Per Share | $0.67 |
Full Cash Flow StatementMargins
Gross margin is 49.16%, with operating and profit margins of 20.59% and -7.74%.
| Gross Margin | 49.16% |
| Operating Margin | 20.59% |
| Pretax Margin | -3.12% |
| Profit Margin | -7.74% |
| EBITDA Margin | 26.79% |
| EBIT Margin | 20.59% |
| FCF Margin | 4.60% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.23% |
| Shareholder Yield | -1.23% |
| Earnings Yield | -6.57% |
| FCF Yield | 3.91% |
Dividend DetailsAnalyst Forecast
The average price target for Teva Pharmaceutical is $25.00, which is 46.54% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.00 |
| Price Target Difference | 46.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.56 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.56 |
| Piotroski F-Score | 7 |